The pharmacokinetic properties of lenampicillin (KBT-1585), a new ampicillin ester, were investigated in 41 healthy volunteers. The maximum concentration of ampicillin in serum after oral administration of 400 mg of lenampicillin was 6.5 jig/ml at 0.70 h, and that after a equimolar dosage of ampicillin was 2.9 ,ug/ml at 0.87 h.
The pharmacokinetic properties of lenampicillin (KBT-1585), a new ampicillin ester, were investigated in 41 healthy volunteers. The maximum concentration of ampicillin in serum after oral administration of 400 mg of lenampicillin was 6.5 jig/ml at 0.70 h, and that after a equimolar dosage of ampicillin was 2.9 ,ug/ml at 0.87 h.
Lenampicillin (KBT-1585), (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl(2S,SR,6R)-6-[(R)-2-amino-2-phenylacetamido]-3 ,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3 .2.0]heptane-2-carboxylate hydrochloride, is a new ampicillin ester.
Lenampicillin is hydrolyzed to ampicillin and acetoin, a natural substance with low toxicity, by intestinal esterase during absorption after oral administration. Antimicrobial activity of lenampicillin has been shown to be equal to that of ampicillin in vitro (9) . In mice, rats, and dogs, lenampicillin shows good absorption (1, 17) , stability in the gastrointestinal tract, and consequently, little disturbance to intestinal microflora (5) .
Based on the results of preclinical studies, lenampicillin is expected to produce a low frequency of adverse effects and to have good uptake in human subjects. The purpose of this study was to investigate the pharmacokinetic properties of lenampicillin in healthy volunteers. Forty-one healthy male volunteers participated in the study after they gave informed consent.
Tablets containing 400 mg of lenampicillin, equivalent to 250 mg of ampicillin, were used in this study. A total of 1 mg of lenampicillin is equivalent to 632 ,ug of ampicillin.
Bioactive compounds in blood and urine were determined after oral administration of 800 mg of lenampicillin in four healthy male volunteers. Materials from urine and serum were separated by thin-layer chromatography on silica gel (Kieselgel 60 F254, acetate ethyl-acetate hydroxide-H20, 70 flow rate, 1.2 ml/min; detection wavelength, 214 nm). The sensitivity limit of the assay was 0.1 ,ug/ml for the bioassay and 0.5 ,ug/ml for HPLC. The ampicillin concentrations in serum and urine, as estimated by HPLC, were consistent with the values obtained by the bioassay. Furthermore, lenampicillin was not detected by HPLC in serum or urine. These results suggest strongly that the bioactive compound in blood is not lenampicillin itself but ampicillin. The major metabolites in addition to ampicillin were a-aminoben-* Corresponding author. zylpenicilloic acid and 5S-a-aminobenzylpenicilloic acid in urine; cumulative urinary excretions from 0 to 6 h was 56.4 + 6.0% (mean ± standard deviation), 13.2 ± 2.9%, and 20.9 + 4.1%, respectively.
In this study the pharmacokinetics of lenampicillin were studied by measuring the concentration of ampicillin in serum and urine. Ampicillin concentrations were determined microbiologically by an agar diffusion method. B. subtilis ATCC 6633, at a concentration of 2.5 x 106 CFU/ml of sensitivity test agar medium (EIKEN Co., Tokyo, Japan), and M. luteus ATCC 9341, at a concentration of 6 x 105 CFU/ml of Tryptosoy agar medium (EIKEN), were employed in the assay as test organisms. Samples were analyzed against a standard curve prepared in pooled human serum for blood and in 1/15 M phosphate buffer (pH 7.0) for urine. The standard curve was linear for 0.16 to 40 ,ug of ampicillin per ml. Urine samples were diluted to an appropriate concentration in the same buffer for assay. The pharmacokinetic parameters were calculated on the basis of a one-compartment open model.
The pharmacokinetics after single oral doses of 400 or 800 mg were determined in five healthy volunteers in fasting state in a cross-over design study. Blood samples were obtained from the antecubital vein just before administration and at 0.25, 0.5, 1, 2, 4, and 6 h after dosing; and urine was collected during the time intervals 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, and 12 to 24 h. A curve showing the concentration of drug in serum is shown in Fig. 1 . The maximum concentration of the drug (Cmax) in serum was 5.8 ± 1.5 ,ug/ml after 400 mg of lenampicillin was administered and 10.4 ± 4.3 ,ug/ml after 800 mg of lenampicillin was administered. The area under the concentration-time curve from 0 to 6 h (AUCo4) was 10.8 ± 1.8 and 19.7 + 6.2 jug. h/ml, the half-life (t1/2) was 0.61 ± 0.26 and 0.83 ± 0.07 h, and cumulative urinary excretion from 0 to 6 h was 48.1 ± 5.3 and 49.5 ± 13.7% ofthe 400-and 800-mg doses, respectively.
A multiple/dose study was conducted in six volunteers. Each subject received 400 mg of lenampicillin 4 times a day for 7 days. No notable pharmacokinetic change was found after repeated administration. AUC was 9.3 ± 3.0 and 9.0 + 4.4 ug -h/ml, ti12 was 0.67 ± 0. 15 Fig. 2 .
The pharmacokinetics of lenampicillin were compared with those of ampicillin. Ten volunteers received 400 mg of lenampiclllin or 250 mg of ampicillin in fasting state in a cross-over design study. Ampicillin concentrations in serum after the administration of lenampicillin and ampicillin were 3.5 + 0.7 and 1.3 ± 0.3 p,g/ml at 0.5 h, 6.0 ± 0.6 and 2.7 0.7 ,ug/ml at 1 h, 2.6 ± 0.7 and 1.7 ± 0.6 ,ug/ml at 2 h, 0.6 + 0.1 and 0.7 + 0.5 ,ug/ml at 4 h, and 0.2 ± 0.2 and 0.2 + 0.2 ,ug/ml at 6 h, respectively. The AUC after lenampicillin and ampicillin administration was 10.8 ± 1.4 and 6.6 ± 2.1 ,ug. h/ml, Cmax was 6.5 + 1.0 and 2.9 ± 0.6 ,ug/ml, Tmax was 0.70 ± 0.10 and 0.87 + 0.21 h, t1/2 was 1.00 ± 0.24 and 1.37 + 0.57 h, and cumulative urinary excretion from 0 to 6 h was 54.5 + 8.4 and 45.7 ± 7.6% of the dose, respectively. Although the AUCo after lenampicillin administration was about 70% greater than that after ampicillin administration, the recovery in the urine was only about 20% greater. This inconsistency is probably due to its oral route of administration, which complicates the rate of absorption and excretion.
The effect of probenecid on the pharmacokinetics of lenampicillin was studied in five volunteers. Each volunteer received 400 mg of lenampicillin orally with or without probenecid in a cross-over design study. The volunteers were given 1 g of probenecid orally 30 min before administration of lenampicillin. Cmax was 6.9 ± 1.7 ,ug/ml and 5.8 ± 1.8 ,ug/ml, Tmax was 0.55 ± 0.15 and 0.87 ± 0.22 h, AUC0-6 was 10.0 ± 2.3 and 14.5 ± 3.0 pug. h/ml, t1/2 was 0.84 ± 0.04 and 1.36 ± 0.25 h, and cumulative urinary excretion from 0 to 6 h was 51.9 ± 6.7 and 30.2 ± 5.5% of the dose with and without probenecid, respectively. This result suggests that lenampicillin is excreted by a tubular secretion mechanism that is competitively inhibited by probenecid.
The pharmacokinetic parameters in the five studies listed above are summarized in Table 1 .
Among the ampicillin esters, pivampicillin (15) , talampicillin (3), and bacampicillin (2) are well known, and their pharmacokinetics have been studied. All of these compounds have been shown to be more absorbed than the parent compound, ampicillin, when given orally (3, 11, 13, 15) . In this study, lenampicillin was also shown to be well absorbed. However, the absorption appeared to be somewhat influenced by food. The influence of food on drug absorption has been reviewed by Welling (16) . It has been observed that the absorption of pivampicillin is reduced when it is administered with a standard breakfast consisting of dairy products as well as eggs, sausage, toast, and milk, resulting in decreased AUC by almost half compared with that obtained in a fasting state (4) . The interaction of talampicillin with food has also been well studied (6) (7) (8) 12) . A decrease in the Cmax and a delay in the Tmax have been shown; however, AUC and urinary recovery were not reduced significantly (6) (7) (8) 12) . It is therefore considered that the bioavailability of talampicillin is not changed by food (6) (7) (8) . Bacampicillin is also not considered to be affected by food (10) . Recently, another result was reported that bacampicillin also showed significant changes in Cmax and Tmax and no significant decrease of AUC and urinary recovery (14) . In our study, AUC and the urinary recovery of lenampicillin were not reduced significantly, but Cmax and Tmax were changed. These results indicate that the bioavailability of lenampicillin also is not influenced by food. Vol. 29, 1986 on September 27, 2017 by guest http://aac.asm.org/ Downloaded from
